Dietary Supplement Listing Act of 2026
- Sponsor
- Rep. Dexter, Maxine [D-OR-3]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Apr 20, 2026
Bottom line
This bill aims to enhance transparency and consumer safety in the dietary supplement market by requiring mandatory product listing with the FDA and creating a public database of supplement information.
What it actually does
This bill mandates that all dietary supplements marketed in the United States must be listed with the Food and Drug Administration (FDA). Manufacturers, packers, or distributors are required to submit detailed information, including product names, ingredients, labels, and claims, to the FDA. The bill also directs the FDA to establish a publicly accessible electronic database containing this information and assigns a unique product listing number to each supplement.
Proponents argue
Proponents argue that mandatory listing will provide the FDA with crucial, comprehensive information about products on the market, which is currently lacking. This increased oversight will enable the agency to more effectively identify potentially harmful or mislabeled products, respond to safety concerns, and ultimately improve consumer protection in the rapidly growing dietary supplement industry.
Opponents contend
Opponents, particularly some industry groups, may contend that this requirement imposes an unnecessary and costly regulatory burden on manufacturers, especially small businesses, which could lead to higher product prices for consumers. They might also argue that existing regulations are sufficient or that the FDA lacks the resources to efficiently manage such a vast database without significant new appropriations.
The bill is relatively short and clearly written, making it accessible for a reader to understand its core provisions within a reasonable timeframe.
Section 2(a), adding new Section 403D(a) and (b) to the Federal Food, Drug, and Cosmetic Act
Establishment of Mandatory Dietary Supplement Listing
This provision mandates that all dietary supplements marketed in the United States must be listed with the Secretary of the FDA. The 'responsible person' (manufacturer, packer, or distributor) must submit detailed information, including product name, responsible person's contact info, an electronic copy of the label, a list of all ingredients (including proprietary blends with confidential amounts), serving information, directions, warnings, allergen statements, form, and claims.
Supporters argue
Supporters argue this is a critical step for FDA oversight, providing the agency with a comprehensive understanding of what products are on the market, which is currently lacking. This information is essential for identifying adulterated or misbranded products and responding to safety concerns.
Critics contend
Some industry stakeholders may argue that this creates an unnecessary administrative burden and cost, especially for smaller businesses, without clear evidence that current regulations are insufficient to protect public health. They might also raise concerns about proprietary information disclosure.
Tradeoffs
Balances the desire for increased public health oversight and transparency against potential compliance costs and administrative burdens for the industry.
Section 2(a), adding new Section 403D(b)(4) to the Federal Food, Drug, and Cosmetic Act
Implementation Timeline and Listing Maintenance
For existing dietary supplements (on the market by January 1, 2027), listing is required within 18 months of enactment, and the product listing number must be on the label within 2 years. New supplements must be listed at the time of introduction into interstate commerce, with the listing number on the label immediately. Responsible persons must also notify the FDA within one year if a product is discontinued and submit changes to listings when labels are modified.
Section 2(a), adding new Section 403D(c) to the Federal Food, Drug, and Cosmetic Act
Creation of Public Database and Confidentiality Protections
The FDA is required to establish and maintain a publicly available electronic database within two years of enactment, containing most of the submitted listing information. This database will be searchable by product listing number and other fields. Crucially, certain information, such as the responsible person's specific contact details (email, foreign agent info) and the amount of ingredients in proprietary blends, will remain confidential and withheld from public disclosure.
Section 2(b), amending Section 403 of the Federal Food, Drug, and Cosmetic Act
Dietary Supplements Deemed Misbranded for Non-Compliance
This provision amends existing law to declare a dietary supplement as 'misbranded' if the responsible person fails to comply with any of the listing requirements, including initial listing, changes to existing listings, or providing additional information upon request. Misbranding can lead to regulatory actions by the FDA, such as product seizure or injunctions.
While the bill requires listing all ingredients in a proprietary blend, it explicitly states that 'the amount per serving of dietary ingredients within a proprietary blend (which shall remain confidential and not subject to public disclosure)' and that this information 'shall be withheld under section 552(b)(3) of title 5, United States Code' (FOIA exemption).
Section 403D(b)(1)(F)(iv) and 403D(c)(3)
Why it matters:This is standard legislative practice for protecting trade secrets while still requiring disclosure to the regulatory agency. It's a common compromise in transparency legislation.
Case for: Industry argues that the exact proportions of ingredients in proprietary blends are trade secrets, and public disclosure would harm their competitive advantage. Providing ingredient names to the public and amounts to the FDA is seen as a reasonable balance.
Case against: Consumer advocacy groups might argue that knowing the exact amounts of active ingredients is crucial for consumers and healthcare providers to assess efficacy and safety, especially for products with multiple ingredients. Without amounts, it's harder to determine if a product contains therapeutic doses or merely 'fairy dust' amounts.
Estimated impact: This impacts the level of transparency for potentially thousands of dietary supplements containing proprietary blends, affecting consumer and scientific understanding of product formulations.
The bill requires listing claims that characterize the relationship of an ingredient to a disease or health condition. However, it includes a proviso: 'provided that no additional listing or change to listing information is required under this paragraph for any minor variation or modification to a claim for which notification under section 403(r)(6) is not required.'
Section 403D(b)(1)(L)(ii)
Why it matters:This is likely intended to reduce administrative burden on manufacturers for trivial changes to claims, aligning with existing FDA guidance on health claims. It prevents constant re-listing for minor wording adjustments.
Case for: Industry would argue this prevents unnecessary paperwork for minor, non-substantive changes, allowing them to update marketing language without triggering a full re-listing process.
Case against: Critics might argue that 'minor variation' could be interpreted broadly, potentially allowing manufacturers to make subtle but significant changes to claims without FDA review or public notification, thus undermining transparency.
Estimated impact: Could affect the frequency and scope of updates to the public database regarding product claims, potentially reducing the administrative load for both industry and the FDA.